Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

Background Pembrolizumab is FDA approved for tumors with tumor mutational burden (TMB) of ≥10 mutations/megabase (mut/Mb). However, the response to immune checkpoint inhibitors (ICI) varies significantly among cancer histologies. We describe the landscape of frameshift mutations (FSs) and evaluated...

Full description

Bibliographic Details
Main Authors: Ignacio Garrido-Laguna, Asaf Maoz, Wungki Park, Abdul Rafeh Naqash, Vaia Florou, Breelyn Wilky, Jonathan Trent, Umang Swami, Garrett Frampton, Heloisa P Soares, Sonam Puri, Aik Choon Tan, Charalampos S Floudas, Carter Norton, Ethan S Sokol, Peter Hosein, Gilberto de Lima Lopes
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/8/e007440.full

Internet

https://jitc.bmj.com/content/11/8/e007440.full

Similar Items